biotherapeutics

A new consortium will characterize 10,000 antibodies to a single standard, aiming to train AI models that flag manufacturing risks before candidates advance.

Explore how charge variant fractionation combined with downstream analysis methods can reveal molecular differences in complex biotherapeutics.

Sessions spanning chemoproteomics, AI-driven proteomics, biotherapeutic characterization, single-cell omics, and spatial multiomics all pointed toward mass spectrometry’s growing role in drug discovery and development.

Learn how to detect aggregation early and quantify proteins, peptides, and ADCs fast with combined UV/Vis and DLS in one low-volume, automated workflow.

The state-of-the-art facility will deliver CGMP plasmid DNA development and manufacturing services by late 2025.

Cell-free gene synthesis removes key bottlenecks in mRNA synthesis, accelerating the development of lifesaving therapies.

Bacterial contaminants in cell cultures pose a significant threat to the biopharmaceutical safety. How do scientists detect these hard-to-spot pests?